MEK activation and MDSC recruitment may be targetable for some breast cancer patients; however, MEK inhibition did not completely reverse suppressive myeloid cell recruitment in vivo, suggesting additional pathways may contribute to this phenotype. This evidence concerns the gene MAP2K7 and breast carcinoma.